Nucleophosmin leukemogenic mutant activates Wnt signaling during zebrafish development
Metrics: PDF 1677 views | HTML 2583 views | ?
Elisa Barbieri1,4, Gianluca Deflorian2, Federica Pezzimenti2, Debora Valli1, Marco Saia1, Natalia Meani1, Alicja M. Gruszka1,*, Myriam Alcalay1,3,*
1Department of Experimental Oncology, Istituto Europeo di Oncologia, Milan, Italy
2The FIRC Institute of Molecular Oncology (IFOM) Foundation, Milan, Italy
3Dipartimento di Oncologia ed Emato-Oncologia, Università degli Studi di Milano, Milan, Italy
4Current address: Gene Expression and Regulation Program, The Wistar Institute, Philadelphia, PA, USA
*These authors contributed equally to this work
Myriam Alcalay, email: [email protected]
Keywords: acute myeloid leukemia, nucleophosmin, zebrafish, primitive hematopoiesis, Wnt signaling
Received: September 17, 2015 Accepted: June 26, 2016 Published: July 28, 2016
Nucleophosmin (NPM1) is a ubiquitous multifunctional phosphoprotein with both oncogenic and tumor suppressor functions. Mutations of the NPM1 gene are the most frequent genetic alterations in acute myeloid leukemia (AML) and result in the expression of a mutant protein with aberrant cytoplasmic localization, NPMc+. Although NPMc+ causes myeloproliferation and AML in animal models, its mechanism of action remains largely unknown. Here we report that NPMc+ activates canonical Wnt signaling during the early phases of zebrafish development and determines a Wnt-dependent increase in the number of progenitor cells during primitive hematopoiesis. Coherently, the canonical Wnt pathway is active in AML blasts bearing NPMc+ and depletion of the mutant protein in the patient derived OCI-AML3 cell line leads to a decrease in the levels of active β-catenin and of Wnt target genes. Our results reveal a novel function of NPMc+ and provide insight into the molecular pathogenesis of AML bearing NPM1 mutations.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.